CIRB Studies

Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.

To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.

Displaying 21 - 30 of 730
Study Number Lead Group Study Title CIRB Study Status
AEWS1031 COG A Phase III Randomized Trial of Adding Vincristine-topotecan-cyclophosphamide to Standard Chemotherapy in Initial Treatment of Non-metastatic Ewing Sarcoma: A Groupwide Phase III Study Pediatric CIRB Available to Open
S1406 SWOG Randomized Phase II Study of Irinotecan and Cetuximab with or without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer Adult CIRB - Early Phase Emphasis Available to Open
9892 ETCTN Phase I Dose-Escalation Bioavailability Study of Oral Triapine in Combination with Concurrent Chemoradiation for Locally Advanced Cervical Cancer (LACC) and Vulvar Cancer Adult CIRB - Early Phase Emphasis Available to Open
ACCL1033 COG A Comprehensive Approach to Improve Medication Adherence in Pediatric ALL: A Group-wide Non-Therapeutic Study Pediatric CIRB Available to Open
S1706 SWOG A Phase II Randomized Trial of Olaparib (NSC-747856) Administered Concurrently with Radiotherapy versus Radiotherapy Alone for Inflammatory Breast Cancer Adult CIRB - Late Phase Emphasis Available to Open
RTOG-1016 RTOG Phase III Trial of Radiotherapy Plus Cetuximab Versus Chemoradiotherapy in HPV-Associated Oropharynx Cancer Adult CIRB - Late Phase Emphasis Available to Open
E2112 ECOG A Randomized Phase III Trial of Endocrine Therapy plus Entinostat/Placebo in Patients with Hormone Receptor-Positive Advanced Breast Cancer Adult CIRB - Late Phase Emphasis Available to Open
S1612 SWOG A Randomized Phase II/III Trial of "Novel Therapeutics" versus Azacitidine in Newly Diagnosed Patients with Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS), Age 60 or Older Adult CIRB - Late Phase Emphasis Available to Open
NRG-GY008 NRG A Phase II Evaluation of Copanlisib (BAY 80-6946); (IND #130822); A Selective Inhibitor of PI3KCA; in Patients with Persistent or Recurrent Endometrial Carcinoma Harboring PIK3CA Hotspot Mutations Adult CIRB - Late Phase Emphasis Available to Open
APEC14B1 COG The Project: Everychild Protocol: A Registry; Eligibility Screening; Biology and Outcome Study Pediatric CIRB Available to Open
Displaying 21 - 30 of 730